Group 1 - AbbVie submitted a new indication application for Upadacitinib to treat adult and adolescent non-segmental vitiligo to the FDA and EMA, potentially making it the first systemic drug for vitiligo globally [1] - AbbVie's total revenue for 2025 reached $61.16 billion, marking an 8.6% year-over-year increase, officially entering the $60 billion club [1] - Global sales of Upadacitinib amounted to $8.30 billion, reflecting a 39.1% year-over-year growth, while sales of Risankizumab reached $17.56 billion, up 49.9% [1] Group 2 - AbbVie's stock price fluctuated between $225.82 (highest on February 6) and $214.04 (lowest on February 5) during the week of February 5 to February 12, with a closing price of $223.19 on February 12, up 1.04% [2] - The pharmaceutical sector rose by 0.83% during the same period, while the Dow Jones index increased by 0.50% [2] Group 3 - AbbVie's immunology business generated $30.4 billion in revenue, a 14% year-over-year increase, becoming the core growth driver [3] - The neuroscience business has upgraded to a core pillar, with Vraylar generating $3.62 billion and Botox in the migraine field generating $3.77 billion [3] - The company acquired Capstan to gain access to the tLNP platform, positioning itself in the cutting-edge CAR-T therapy field [3] Group 4 - On February 5, multiple Wall Street firms updated their ratings, with TD Cowen maintaining a buy rating and a target price of $280, while Evercore lowered its target price to $228, and UBS maintained a hold rating with a target price of $230 [4] - Analysts are focusing on the company's pipeline progress and the potential for upward revisions in earnings guidance [4]

Core Insights - The global pharmaceutical industry is witnessing a significant shift in the rankings of best-selling drugs, with several products surpassing $10 billion in sales for 2025 [1][2]. Group 1: Sales Performance - Novo Nordisk's semaglutide briefly topped the sales chart in Q1 2025 but was ultimately surpassed by Eli Lilly's tirzepatide, with both drugs exceeding $30 billion in sales [1][3]. - Tirzepatide achieved a remarkable year-on-year sales growth of 121%, while semaglutide's growth was only 13% [3]. - The sales figures for semaglutide in the first half of 2025 reached $16.683 billion, maintaining its position as a top-selling drug [3]. Group 2: Competitive Landscape - The GLP-1 drug class is experiencing intense competition, with both tirzepatide and semaglutide being key players [4][5]. - The market is dominated by Novo Nordisk and Eli Lilly, but Chinese pharmaceutical companies are also making significant strides in this area [5][6]. - New GLP-1 drugs are under development, including Novo Nordisk's CagriSema and Eli Lilly's retatrutide, which shows potential for greater weight loss than tirzepatide [5]. Group 3: Oncology and Autoimmune Drugs - The PD-1 inhibitor pembrolizumab (Keytruda) remains a top seller in oncology, with sales reaching $31.68 billion in 2025, despite falling to third place [7]. - Nivolumab (Opdivo) also crossed the $10 billion mark, achieving sales of $10.29 billion [8]. - In the autoimmune disease sector, drugs like dupilumab and risankizumab achieved sales of $17.8 billion and $17.562 billion, respectively [8]. Group 4: Anticoagulants - The anticoagulant apixaban continues to show strong sales growth, with BMS reporting $14.443 billion in sales, a year-on-year increase of 8% [9]. - Pfizer's reported revenue from apixaban reached $8 billion, making it their second-largest selling product [9].

Core Insights - The pharmaceutical industry is witnessing a significant shift in the rankings of top-selling drugs, with several products surpassing $10 billion in sales for 2025 [1][2] - The competition in the GLP-1 drug category is intensifying, with new entrants like semaglutide and tirzepatide rapidly gaining market share [3][4] Group 1: Top-Selling Drugs - Tirzepatide from Eli Lilly has achieved sales of $365.07 billion, making it the top-selling drug of 2025 [2][3] - Semaglutide from Novo Nordisk follows closely with sales of $361 billion, having briefly surpassed Merck's pembrolizumab (Keytruda) in Q1 2025 [1][3] - Pembrolizumab (Keytruda) recorded sales of $316.8 billion, maintaining a strong position despite falling to third place [7][8] Group 2: Market Dynamics - The sales growth of tirzepatide is remarkable, with a year-on-year increase of 121%, while semaglutide's growth is only 13% [3] - The competitive landscape for GLP-1 drugs is evolving, with multiple companies, including domestic Chinese firms, entering the market with biosimilars and new formulations [4][6] - Novo Nordisk and Eli Lilly are both developing next-generation GLP-1 drugs, with Novo Nordisk's CagriSema and Eli Lilly's retatrutide showing promising clinical results [5] Group 3: Other Notable Drugs - Other significant drugs include nivolumab (Opdivo) from Bristol-Myers Squibb, which achieved sales of $102.87 billion, and daratumumab (Darzalex) with sales of $143.51 billion [8][9] - Apixaban (Eliquis), a leading anticoagulant, continues to grow, with Bristol-Myers Squibb reporting sales of $144.43 billion, reflecting an 8% increase [9]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 1.07%, ranking 26th among 31 primary industries, outperforming the CSI 300 index which fell by 1.19% [4][15] - The valuation of the pharmaceutical and biotechnology industry as of January 23, 2026, is a PE (TTM overall method, excluding negative values) of 30.31x, down from 30.56x in the previous period, indicating a downward trend below the average [4][19] - The top three sub-industries by PE are vaccines (47.34x), hospitals (44.94x), and other medical services (40.38x), while the lowest valuation is in pharmaceutical circulation (15.31x) [4][19] - During the reporting period, 34 listed companies in the pharmaceutical and biotechnology sector saw a net reduction of 2.125 billion yuan in shareholder holdings, with 2 companies increasing holdings by 63 million yuan and 32 companies reducing holdings by 2.189 billion yuan [4] Industry Review - The report highlights significant developments in the pharmaceutical retail sector, emphasizing the need for transformation from traditional drug sales to comprehensive health services [24][25] - The Ministry of Commerce and other departments issued opinions to promote high-quality development in the pharmaceutical retail industry, projecting a market size increase from 2.41 trillion yuan in 2020 to 2.95 trillion yuan by 2024, a growth of 22.4% [24][25] - The report also discusses the approval of new drugs and treatments, including the PD-1/VEGF bispecific antibody RC148 by Rongchang Biopharmaceuticals, which has a potential total payment of up to 4.95 billion USD [7][50] Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with differentiated pipelines that have received validation from high-quality collaborations with multinational pharmaceutical companies, particularly in key areas such as ADC, bispecific antibodies, and siRNA therapies [7]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 1.07%, ranking 26th among 31 primary industries, outperforming the CSI 300 index which fell by 1.19% [4][15] - The valuation of the pharmaceutical and biotechnology industry as of January 23, 2026, is a PE (TTM overall method, excluding negative values) of 30.31x, down from 30.56x in the previous period, indicating a decline in valuation below the average [4][19] - The top three sub-industries by PE (TTM overall method, excluding negative values) are vaccines (47.34x), hospitals (44.94x), and other medical services (40.38x), while the lowest valuation is in pharmaceutical circulation (15.31x) [4][19] - During the reporting period, 34 listed companies in the pharmaceutical and biotechnology sector saw a net reduction in shareholder holdings amounting to 2.125 billion yuan, with 2 companies increasing holdings by 63 million yuan and 32 companies reducing holdings by 2.189 billion yuan [4] Industry Trends - The 2026 JPM Conference highlighted Chinese innovative drugs as a global focus, with several Chinese companies showcasing advancements in PD-1/VEGF bispecific antibodies, ADCs, and cell therapies [7] - The report suggests focusing on innovative pharmaceutical companies with differentiated pipelines that have received validation through high-quality collaborations with multinational pharmaceutical companies, particularly in key areas such as ADCs, bispecific antibodies, and siRNA therapies [7] Important Industry News - The Ministry of Commerce and eight other departments issued opinions on promoting high-quality development in the drug retail industry, projecting a growth in the drug circulation market from 2.41 trillion yuan in 2020 to 2.95 trillion yuan by 2024, a 22.4% increase [24] - The National Healthcare Security Administration released guidelines for pricing projects related to surgical and treatment auxiliary operations, aiming to standardize and promote the use of advanced medical technologies [27][28] - Notable approvals include Daiichi Sankyo's "Trastuzumab Deruxtecan" for advanced HER2-positive gastric cancer, and AbbVie’s "Risankizumab" for ulcerative colitis, showcasing significant advancements in treatment options [38][44]

Core Viewpoint - AbbVie announced the approval of Risankizumab (brand name: Skyrizi) for a second indication in China, aimed at treating adult patients with moderate to severe active ulcerative colitis (UC) who have inadequate response, loss of response, or intolerance to traditional or biologic therapies [1] Group 1: Product Information - Risankizumab is an IL-23 inhibitor that selectively blocks IL-23 by binding to the IL-23p19 subunit, which is involved in inflammatory processes related to various chronic immune-mediated diseases [1] - The approval for the new indication is based on positive results from two Phase III clinical trials, INSPIRE and COMMAND [1] Group 2: Clinical Trial Results - In the INSPIRE induction trial, Risankizumab significantly improved clinical remission rates at 12 weeks compared to placebo (20.3% vs 6.2%; adjusted between-group difference 14.0% [95% CI: 10.0%–18.0%]; P<0.001) [1] - In the COMMAND maintenance trial, both 180mg and 360mg maintenance doses showed significantly better clinical remission rates at 52 weeks compared to the placebo group (40.2% vs 37.6% vs 25.1%) [1] Group 3: Market Context - Risankizumab was first approved in China on March 10, 2025, for treating adult patients with moderate to severe active Crohn's disease who have inadequate response, loss of response, or intolerance to traditional or biologic therapies [1]

Core Insights - The implementation of the new national medical insurance drug list in 2025 has enabled the first medical insurance prescription for Risankizumab in Nanjing, significantly reducing the economic burden on Crohn's disease patients and improving their quality of life [1][3]. Group 1: Disease Overview - Crohn's disease, a major subtype of inflammatory bowel disease (IBD), is characterized by chronic recurrent inflammation of the digestive tract and is often referred to as "green cancer" due to its severe impact on patients' quality of life [3]. - The incidence of IBD in East Asia is accelerating, with the number of patients in China increasing at a rate of 5% to 10% annually [3]. Group 2: Treatment Advancements - Risankizumab has demonstrated significant therapeutic advantages in clinical studies and has been approved in over 40 countries, benefiting more than 40,000 patients with proven safety and efficacy [3]. - As the first interleukin-23 inhibitor approved for treating moderate to severe active Crohn's disease, Risankizumab offers a more precise treatment option for patients [3]. Group 3: Clinical Center Development - The Gastroenterology Department at Taikang Xianlin Gu Lou Hospital is recognized as a provincial clinical key specialty and has made significant advancements under the leadership of renowned expert Professor Zou Xiaoping [5]. - The newly established Small Intestine and Inflammatory Bowel Disease Diagnosis and Treatment Center focuses on key aspects of IBD management, integrating diagnostic and therapeutic approaches for comprehensive patient care [6].

Core Points - The new "Chongqing Drug Directory (2025)" has been officially implemented since January 1, 2025, which includes 3,253 drugs in the National Drug Directory and additional local supplements [1] - The updated medical insurance directory has added 114 new drugs with an average price reduction of over 60%, significantly alleviating the financial burden on patients [2] - The new insurance directory for commercial health insurance has included 19 innovative drugs, enhancing treatment options for patients with various conditions [7] Group 1: National Drug Directory Changes - The National Drug Directory (2025) includes 3,253 drugs and 892 traditional Chinese medicine pieces, with Chongqing adding 201 traditional Chinese medicine pieces and 87 medical institution preparations [1] - The average price reduction for newly added drugs is over 60%, benefiting patients with conditions such as cancer and chronic diseases [2] - Specific examples include the price drop of the targeted drug for lung cancer from 12,900 yuan to 4,000 yuan per box [2] Group 2: Chronic Disease Treatment - The new directory has expanded the coverage of 65 drugs, including new indications for existing treatments, such as the inclusion of new targets for non-small cell lung cancer [4] - The price of the drug for Crohn's disease has been reduced from 22,045.02 yuan to 8,130.49 yuan for the intravenous form [3] - The expanded reimbursement range allows for more personalized treatment plans for early-stage breast cancer patients [4] Group 3: Commercial Health Insurance Innovations - The "Commercial Health Insurance Innovative Drug Directory (2025)" includes 19 new drugs, such as targeted therapies for various cancers and CAR-T products for blood cancers [7] - The directory serves as a reference for insurance companies, potentially increasing patient enrollment in commercial health insurance [7] - A new multi-layered medical insurance settlement platform has been launched to streamline the claims process for patients [8]

Investment Rating - The report does not explicitly state an investment rating for the interleukin industry Core Insights - The interleukin family consists of various cytokines that play significant roles in immune regulation, inflammation, and cancer, with many related drugs and clinical pipelines in development [4][5] - The IL-12 and IL-23 cytokines are crucial in immune modulation and have become important therapeutic targets for autoimmune diseases such as psoriasis and Crohn's disease [9][10] - The market for IL-4Rα drugs in allergic diseases is expanding, with two main drugs approved in China for treating allergic asthma and other conditions [16] - IL-1β inhibitors are gaining traction in gout treatment, with a notable increase in patient numbers projected for high uric acid levels and gout by 2030 [23][25] - Artificial intelligence is enhancing drug development processes across various stages, significantly reducing the time required for drug discovery and optimization [31][32] Summary by Sections Interleukin Family Overview - The interleukin family includes multiple members categorized into several groups, each with distinct roles in immune response and disease [3][4] - Key interleukins such as IL-1, IL-2, IL-6, IL-10, and IL-17 are involved in autoimmune and inflammatory diseases, with existing drugs and clinical pipelines targeting these cytokines [5] Market Status of IL-12/IL-23 - Several drugs targeting IL-12 and IL-23 have been approved for treating autoimmune diseases, with notable examples including Ustekinumab and Guselkumab [8][10] - The first fully human monoclonal antibody targeting IL-12/IL-23, Iroquois, is set to launch in 2025 for moderate to severe plaque psoriasis [10] IL-4 in Allergic Diseases - Two IL-4Rα drugs have been approved in China for allergic diseases, with Dupilumab included in the national medical insurance list [16] - The report outlines ongoing clinical trials for additional IL-4Rα therapies targeting various allergic conditions [17] IL-1β Inhibitors in Gout Treatment - The report highlights the increasing prevalence of high uric acid and gout, with projections indicating significant growth in patient numbers by 2030 [21][23] - The first IL-1β monoclonal antibody, Canakinumab, has been approved for gout treatment, with a projected global sales figure of $1.5 billion by 2024 [25] Role of Artificial Intelligence in Drug Development - AI is transforming drug discovery by streamlining processes and improving efficiency, reducing the time for lead compound optimization from approximately 65 months to 30 months [32] - The integration of AI in drug development enhances the accuracy of personalized medicine and accelerates the identification of effective drug candidates [31][32]

Group 1: Market Overview - The CITIC Pharmaceutical Index increased by 1.2% during the week of June 3-6, 2025, outperforming the CSI 300 Index by 0.3 percentage points, ranking 16th among CITIC's primary industry classifications [1] - Year-to-date, the CITIC Pharmaceutical and Biotechnology Index has risen by 8.3%, surpassing the CSI 300 Index by 9.9 percentage points, ranking 5th among CITIC's industry classifications [1] - The top five performing stocks for the week included Yiming Pharmaceutical (+33.09%), Wanbangde (+32.59%), Anglikang (+30.28%), Xinnowei (+21.36%), and Haichen Pharmaceutical (+20.93%) [1] Group 2: Patent Cliff and Market Opportunities - By 2037, 27 blockbuster drugs with projected sales exceeding $4 billion in 2024 will face patent expiration, creating a market opportunity of over $240 billion for new entrants [2][12] - China is positioned as a core player in global innovative drug supply, leveraging its technological platforms and research efficiency, with the highest number of clinical pipelines in cell therapy, ADC, and bispecific antibodies [2][21] - The projected revenue from licensing agreements for Chinese projects from 2020 to 2025 is estimated to generate approximately $8.2 billion in net profit, translating to a potential market capitalization increase of $81.7 billion based on a 10x PE ratio [2] Group 3: Investment Recommendations - Focus on authorized blockbuster products with overseas clinical progress, including companies like Kangfang Biotech, Kelun Biotech, and Sanofi [2] - Potentially significant products for licensing out include Innovent Biologics, CSPC Pharmaceutical Group, and Zai Lab [2] - Companies with approved products showing strong commercialization performance include BeiGene, Kingsoft Biotech, and Hutchison China MediTech [2] Group 4: Mid to Long-term Investment Strategy - The investment strategy emphasizes three main lines: innovation, recovery, and policy support [4] - The innovation line focuses on biopharmaceuticals with competitive advantages in international markets and companies with second growth curves in pharmaceuticals [4] - The recovery line anticipates a rebound in medical device tenders and consumer healthcare, while the policy line supports high-dividend companies and encourages mergers and acquisitions [4]